475 Eli Lilly and Company $LLY Shares Sold by Moss Adams Wealth Advisors LLC

Moss Adams Wealth Advisors LLC lessened its position in Eli Lilly and Company (NYSE:LLY) by 9.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,303 shares of the company’s stock after selling 475 shares during the quarter. Eli Lilly and Company accounts for approximately 0.3% of Moss Adams Wealth Advisors LLC’s portfolio, making the stock its 27th largest holding. Moss Adams Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $4,979,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Marshall & Sterling Wealth Advisors Inc. lifted its holdings in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares during the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Eli Lilly and Company in the first quarter worth approximately $42,000. Foresight Capital Management Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the third quarter worth $49,000. Caitlin John LLC purchased a new position in shares of Eli Lilly and Company in the second quarter worth $64,000. Finally, IMG Wealth Management Inc. boosted its holdings in shares of Eli Lilly and Company by 500.0% during the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock worth $72,000 after purchasing an additional 50 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. The Goldman Sachs Group reissued a “buy” rating and set a $1,413.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, October 20th. Scotiabank raised their target price on shares of Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a research report on Friday. Citigroup lifted their target price on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research note on Friday. BMO Capital Markets reiterated an “outperform” rating and issued a $1,650.00 price objective on shares of Eli Lilly and Company in a report on Friday. Finally, Argus upped their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,398.43.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $1,415.64 on Monday. The firm’s 50-day moving average price is $1,197.72 and its 200-day moving average price is $1,092.57. Eli Lilly and Company has a 52-week low of $834.19 and a 52-week high of $1,449.68. The company has a market cap of $1.33 trillion, a PE ratio of 45.95, a PEG ratio of 1.80 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, beating the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm’s quarterly revenue was up 38.6% on a year-over-year basis. During the same period in the previous year, the company earned $7.02 earnings per share. As a group, analysts anticipate that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 22.46%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q3 results substantially beat expectations. Revenue rose 39% year over year to $24.4 billion, while adjusted EPS was $7.48 versus the $5.68 consensus estimate. Mounjaro sales increased 65% to $10.7 billion and Zepbound sales rose 49% to $5.35 billion. Lilly third-quarter results
• Positive Sentiment: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion, up from $85 billion-$87 billion previously. Strong demand, broader Medicare access and growing middle-income adoption are supporting expectations for continued GLP-1 expansion. Q3 earnings call highlights
• Positive Sentiment: Analysts raised their price targets and maintained bullish ratings. Scotiabank lifted its target to $1,605 with a “sector outperform” rating, Morgan Stanley raised its target to $1,596 with an “overweight” rating, and RBC moved to $1,600 with an “outperform” rating. Analyst commentary
• Positive Sentiment: Pipeline and portfolio diversification offer additional upside. Positive Phase 3 retatrutide data strengthened Lilly’s competitive position against Novo Nordisk, while oncology, immunology and neuroscience products are beginning to contribute more meaningfully. Lilly growth opportunities
• Negative Sentiment: Investors face execution and valuation risks. Realized prices fell 15%, meaning volume growth must continue to offset pricing pressure. Results also benefited from roughly $900 million in one-time items, and acquired in-process research charges weighed on earnings. With GLP-1 drugs representing a large share of revenue and the stock near its high, expectations are elevated. Reuters earnings report

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 in the last quarter. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.